Shares of United Therapeutics (UTHR) and Liquidia (LQDA) are moving sharply in opposite directions in Friday afternoon trading. Shares of United ...

Although BTIG still believes Liquidia has favorable odds of prevailing against United’s ‘327 patent, the firm reduced the probability of success for Liquidia’s drug, Yutrepia, in treating pulmonary ...

We sifted through the Finviz stock screener to compile a list of the top 10 biotech stocks with an upside potential of over ...

In a report released yesterday, Andreas Argyrides from Oppenheimer maintained a Sell rating on Liquidia Technologies, with a price target of $6.00. The company’s shares closed yesterday at $19.26.